Clinical trial NCT00135668: Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room
Official title: A Phase 2 Multicenter, Randomized, Double-blind, Parallel Group, Dose-ranging, Effect-controlled Study to Determine the Pharmacokinetics and Pharmacodynamics of Sodium Nitroprusside in Pediatric Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hypotension
Keywords: children
sodium nitroprusside
controlled hypotension
dose-response
pharmacokinetics
pharmacodynamics
safety
efficacy
Lead sponsor: The Emmes Company, LLC
Sponsor class: INDUSTRY
Collaborators: name: Stanford University
name: Duke University
First posted: 2005-08-26
Enrollment: 211
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sodium nitroprusside (SNP) has been approved for control of blood pressure in adults, yet there are no controlled studies in children. The purpose of this study is to determine the efficacy and safety of sodium nitroprusside in children who will be having surgery, and who require blood pressure lowering in order to decrease the amount of blood loss during their surgery.

Detailed description: The trial is a multicenter randomized, double-blind, parallel group, dose-ranging, effect-controlled study examining the effects of sodium nitroprusside in pediatric subjects requiring relative hypotension during a surgical or medical procedure. The goal is to establish the starting and maximum infusion rates that afford optimum blood pressure control in children and a safe dosing regimen in children. The objective is to describe the relationship between the infusion rate of nitroprusside and changes in blood pressure.

The specific aims of this trial are:

1. To define the onset and offset of blood pressure lowering effects of nitroprusside to obtain adequate instructions for dose titration in the pediatric population.
2. To construct a dose-response model that defines the relationship between nitroprusside infusion rate and changes in blood pressure in pediatric subjects.
3. To assess the safety of nitroprusside administration in pediatric subjects requiring controlled reduction of blood pressure.

Eligibility criteria: Inclusion Criteria:

Study subjects must meet all of the following criteria:

* Subject is less than 17 years of age
* Neonates must be full-term gestation and have a body weight of at least 2.5 kg
* Subject requires pharmacologically-induced hypotension for acute blood pressure management for surgery or other invasive procedure, e.g., cerebral artery embolization
* Duration of the subject's controlled hypotension is expected to be ≥ 2 hours
* Subject requires general anesthesia with endotracheal intubation
* Subject requires placement of intra-arterial line during the surgical or medical procedure
* The subject's parent or legal guardian gives permission (informed consent) and subject gives assent when appropriate.

Exclusion Criteria:

Subjects will be excluded if any of the following criteria exist:

* Subject has a known allergy to SNP
* Subject has a known mitochondrial cytopathy with a disorder of oxidative phosphorylation or of respiratory chain enzymes
* Subject has a contraindication to vasodilator therapy for control of blood pressure during surgery or procedures
* Subject has participated in other clinical trials for investigational drugs and/or devices within 30 days prior to enrollment
* Subject has any serious medical condition which, in the opinion of the investigator, is likely to interfere with study procedures
* Subject is moribund (death likely to occur within 48 hours)
* Subject has a positive result for the urine or serum human chorionic gonadotropin (HCG) test administered at screening.

Primary outcomes:
measure: Change in Mean Arterial Pressure (MAP) From the Baseline MAP
timeFrame: Approximately 30 minutes
measure: Overall Summary of Tolerability/Adverse Events (AEs) for ITT Safety Population
timeFrame: 30 days
Secondary outcomes:
measure: Change From Baseline MAP Nitroprusside Infusion During the Blinded Infusion;
timeFrame: 25 minutes
measure: Infusion Rate of Sodium Nitroprusside That Reduces MAP to a Predetermined Clinically Meaningful Target Value +/- 10%;
timeFrame: Up to the end of open label treatment (Approximately 120 minutes)
measure: Number of Participants Who Reach Target MAP;
timeFrame: To the end of open label treatment (approximately 120 minutes)
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
Study officials:
affiliation: Stanford University
name: Gregory Hammer, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Duke University
name: Scott Schulman, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Drover DR, Hammer GB, Barrett JS, Cohane CA, Reece T, Zajicek A, Schulman SR. Evaluation of sodium nitroprusside for controlled hypotension in children during surgery. Front Pharmacol. 2015 Jul 6;6:136. doi: 10.3389/fphar.2015.00136. eCollection 2015.
citation: Hammer GB, Connolly SG, Schulman SR, Lewandowski A, Cohane C, Reece TL, Anand R, Mitchell J, Drover DR. Sodium nitroprusside is not associated with metabolic acidosis during intraoperative infusion in children. BMC Anesthesiol. 2013 Apr 30;13:9. doi: 10.1186/1471-2253-13-9.